Hemispherx Comments on $500+ Million Market Opportunity for Ampligen®, the Only Late Stage ME/CFS Candidate in the U.S.
HEMISPHERX BIOPHARMA (HEB)
NASDAQ:AMEX Investor Relations:
hemispherx.net/mobile/investor-relations.php
Company Research
Source: GlobeNewswire
ORLANDO, Fla., Jan. 23, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American:HEB), focused on pharmaceutical research, today commented on the overall market opportunity for its Ampligen® drug candidate in treating Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), given the recent announcement by clinicians regarding the failure of Rituximab ME/CFS trial in Europe. See Link: http://simmaronresearch.com/2017/11/norwegian-rituximab-chronic-fatigue-syndrome-mecfs-trial-fails/ ME/CFS is a serious, debilitating condition that imposes a burden of illness on millions of people in the U.S. and around the world, leaving hundreds of thousands seriously disabled worldwide. ME/CFS can cause significant impairment and disabilities that have negative economic consequences at both the individual and the societal level. At least one-quarter of ME/CFS patients are house- or bed-bound at some point in their lives (Marshall et al., 2011; NIH, 2011; Shepherd and Chaudhuri, 200
Show less
Read more
Impact Snapshot
Event Time:
HEB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HEB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HEB alerts
High impacting HEMISPHERX BIOPHARMA news events
Weekly update
A roundup of the hottest topics